TRANSCATHETER VERSUS SURGICAL AORTIC VALVE REPLACEMENT: FIRST EXPERIENCE WITH A NEW TAVI SYSTEM.

Objective: The aim: to reveal early results after transapical TAVI with a new self-manufactured XPand system, comparing them with SAVR and common transfemoral TAVI outcomes.

Patients And Methods: Materials and methods: Eighty-four patients (mean age 79,5±10,2 years) with severe aortic stenosis were operated on from January 2016 to February 2019. Nine patients had undergone the TAVI (two with transfemoral access route and seven with transapical, using the XPand system).

Percutaneous closure of patent ductus arteriosus with the Nit-Occlud patent ductus arteriosus device in 268 consecutive cases.

Background: The pfm Nit-Occlud patent ductus arteriosus (PDA) device is well established for interventional closure of PDA. However, there are still limited data concerning its efficacy and follow-up in larger patient groups.

Aims: This study aimed to evaluate the safety and efficacy of the Nit-Occlud PDA device, implanted both through transpulmonary and transaortic approach, in a large cohort.